Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2020, with a filing date of January 13, 2020. The document serves as a transaction notification under Rule 13a-16 or 15d-16, detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific equity transactions.
| Transaction Type | Instrument | Price per Share | Total Volume per Executive |
|---|---|---|---|
| Acquisition | Ordinary Shares (25 pence each) | £18.00 | 14 shares |
Each transaction consisted of 7 partnership shares and 7 matching shares.
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document is a routine disclosure of insider trading activity compliant with regulatory requirements.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a record of share acquisitions executed on January 10, 2020, on the London Stock Exchange (XLON).
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, indicating standard executive compensation activity rather than open market speculation.
- Participants: The filing covers 11 individuals, including the CEO (Ms E Walmsley), President of Global Vaccines (Mr R Connor), and other senior executives and their associated persons.
- Transaction Date: All transactions occurred on January 10, 2020.
- Price Consistency: All shares were acquired at a uniform price of £18.00 per share.
- Volume: The volume per individual was minimal (14 shares), typical for matching share plans.